ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

4 links0 made here, not in the record8 judgments2 judges (the rules as one: Rule based)2 record changes seen
Model not recordedRule basedRecord updated on ClinicalTrials.gov
Sep 28Oct 5Oct 12Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT06806852A Study to Test WhetherTreatment With BI 770371 inCombination WithPembrolizumab With orWithout Cetuximab HelpsPeople With Head and NeckCancer Compared WithBoehringer IngelheimPhase 1 · active not recruitinRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Sep 30 · ClinicalTrials.gov record · Version of 2026-09-30Oct 28 · ClinicalTrials.gov record · Version of 2026-10-28Version of 2026-10-28CONDITIONSSquamous Cell Carcinoma of …The registry's MeSH filing›Nov 14 · Rule based · Finest filed termAs of now · Rule based · Main conditionMain conditionDRUGSAnti-SIRPa Monoclonal Antib…Entry “BI 770371”, read by our name r…›Nov 1 · A model not recorded · TestedNov 18 · Rule based · BackgroundTestedPembrolizumabIntervention entry›Nov 1 · A model not recorded · BackgroundNov 18 · Rule based · TestedBackgroundCetuximabIntervention entry›Nov 1 · A model not recorded · BackgroundNov 18 · Rule based · BackgroundBackground

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Anti-SIRPa Monoclonal Antibody BI 770371

From the registry record2 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “BI 770371”the record gives no role
→judged→changed
How the 2 judgments split50%of judgments with a known value say Tested
Tested · 1
Background · 1

All judgments on this study

WhenLinkJudgeDecisionState
Sep 30The record itselfClinicalTrials.gov recordVersion of 2026-09-30Record change
Oct 28The record itselfClinicalTrials.gov recordVersion of 2026-10-28Record change
Nov 1Anti-SIRPa Monoclonal Antibody BI 770371A model not recordedTestedCurrent
Nov 1PembrolizumabA model not recordedBackgroundCurrent
Nov 1CetuximabA model not recordedBackgroundCurrent
Nov 14Squamous Cell Carcinoma of Head and NeckRule based · condition-kind ruleFinest filed termCurrent
Nov 18Anti-SIRPa Monoclonal Antibody BI 770371Rule based · role ruleBackgroundOverridden
Nov 18PembrolizumabRule based · role ruleTestedOverridden
Nov 18CetuximabRule based · role ruleBackgroundAgrees
As of nowSquamous Cell Carcinoma of Head and NeckRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.

How a condition link is counted

For each condition a study is filed under: whether it is the study's own condition at the finest the study states it, a wider one, a general category, or filed by mistake; and whether it is the main condition, a setting the study names, or only how it was filed.

A decision on file for one study overrides it, with who made it and when.